M-2900 Motesanib, Free Base, 99%

Synonyms : [AMG-706]

  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 36
  • 33
  • 28
  • 4,000
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 75
  • 69
  • 60
  • 8,400
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 112
  • 104
  • 89
  • 12,500
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 198
  • 183
  • 158
  • 22,000
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 367
  • 340
  • 293
  • 40,900
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 860
  • 798
  • 688
  • 95,800
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 1,590
  • 1,477
  • 1,273
  • 177,100
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 373.45
  • C22H23N5O
  • [453562-69-1]
  • M.I. 14: 10338

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; soluble in ethanol at 40 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

  • The CAS number for this motesanib free base product is given above. The CAS number of the diphosphate salt is 857876-30-3.
  • Another CAS number previously assigned to motesanib free base, namely 894356-47-9, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
Missing